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ABSTRACT
In 2001, the National Cholesterol Education Program (NCEP) expanded their
guidelines for evaluation and treatment of hyperlipidemia which includes not only a low
cholesterol diet and exercise, but also the use of plant stands such as Flaxseed and
Soluble fiber. According to the NCEP III guidelines, women with mild hyperlipidemia
and low risk cardiac factors would not qualify for drug therapy to control their
cholesterol. However, the use of plant stanols could be used as an alternative. As there
are limited studies involving postmenopausal women in regards to treatment of heart
disease, there is virtually no information or research on perimenopausal women who may
be at increase risk for Coronary Artery Disease. This experimental pilot study evaluated
the effects of Flaxseed SDG on perimenopausal women with mild hyperlipidemia to see
if this could prevent advancement of hyperlipidemia.
11 perimenopausal women between the ages of 36-48 years with mild
hyperlipidemia were involved in a 14 week randomized, double blind, experimental pilot
study. Subjects were randomized into control Group 1 of Psyllium 11.7gm/day (n=5) and
the experimental Group 2 of Flaxseed SDG (Brevail) 200mg/day (n=6). The study
included an eight week period on the study product and this was followed by two
washout periods at two weeks and then four weeks. Lipid levels and diet assessment were
evaluated at each time point of the study.
Results showed the Brevail SDG group had significant findings for the
VLDL Cholesterol-direct during all three time points of the study (p=0.047, 0.031, 0.011)
and for Triglycerides at time point 1 vs. 2 and 2 vs. 3 (p= 0.043, 0.047). The Psyllium
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group showed statistical significance for improvement of VLDL Cholesterol-direct levels
between time point 1 vs. 3 (p=.021).
There was a trend for improvement of lipid values for LDL-C, Lp(a), and hsCRP
while on the Brevail SDG and an improvement of Total Cholesterol, HDL-C, and NonHDL-C at the six week washout period. The Psyllium group showed a trend for
improvement of total Cholesterol, LDL-C, Non-HDL-C, and hsCRP while on the product
and the HDL-C, Triglycerides, VLDL-C, and Lp(a) showed an improvement in values
during the six week washout period.
In conclusion, due to the small sample size of the study, there was no statistically
significant findings to support that Brevail SDG can improve lipid levels in
perimenopausal women with mild hyperlipidemia. However, there was a favorable trend
in improvement of LDL-c, Lp(a), and hsCRP values while taking Brevail SDG.
Therefore, based on the findings of the study, it would be worthwhile to repeat this study
on a larger basis to determine if there is significant data to support that flaxseed can
improve cholesterol levels and prevent the risk of progressing to CHD in perimenopausal
women with mild hyperlipidemia.
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1
THE EFFECT OF FLAXSEED SDG ON PERIMENOPAUSAL WOMEN WITH
MILD HYPERLIPIDEMIA

CHAPTER I
Introduction
Coronary heart disease (CHD) has been considered the leading cause of mortality
among men compared to women. However CHD is now the leading cause of death in
women affecting 500,000 American women per year (Haan, 1999). Women's prognosis
for heart disease is worse than for men and age mortality rate for CHD in women is four
to six times higher than mortality from breast cancer (Bedinghaus, 2001). A woman's
chance for CHD can progress at a higher rate after menopause. It is believed that
endogenous estrogen acts as a protector against heart disease in premenopausal women
(Knapp, 2002). During this time, women lag behind men by ten years for the risk of
CHD, however with onset of menopause, their risk for heart disease can increase due to
changes in lipid metabolism and atherosclerosis progressing at a faster rate compared to
men. High total cholesterol and LDL-C (low-density lipoprotein) levels are considered to
be a high risk factor for women compared to men (Knapp, 2002). In women, LDL-C and
total cholesterol levels increase after age 55 and can peak between 55-65 years of age
(Bedinghaus, 2002). Whereas, in the middle age population of women, low HDL-C
(High-density lipoprotein) and elevated Triglyceride levels are the factors for increase
risk of CHD (Knapp, 2002)
Other risk factors for CHD include age, hypertension, family history, obesity,
diabetes, inactivity, and metabolic syndrome. Metabolic syndrome is defined as a
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combination of conditions including diabetes, hypertension, hyperlipidemia, obesity,
and clotting abnormalities that can put people at risk for CHD (Knapp, 2002).
With Coronary heart disease being so prevalent in postmenopausal women, there
has been a history of limited studies involving women in regards to heart disease and
treatment even though cardiac disease in women has a higher mortality rate than men.
As there are limited studies involving postmenopausal women in relation to heart
disease and treatment there seems to be virtually no information or research done on
perimenopausal women who may be at risk for CHD. The aim of this study is to evaluate
alternative treatments for perimenopausal women who are considered borderline for
hyperlipidemia and to see if this will benefit this particular population of women from
progressing into CHD once they have entered menopause.
Background
Historical Aspects of Omitting Women from Medical Research
The statistics for women with CHD is increasing substantially. Since 1984,
women in the United States have outnumbered men dying from cardiovascular disease.
One in eight women between the ages of 45-54 years have shown clinical evidence of
CHD and the number increases to one in three after the age of 65 years (Bedinghaus,
2001). A woman has a 42% chance of dying after a heart attack compared to 24% for
men (AHRQ, 2003). A younger woman less than 50 years of age who had an Anterior
Myocardial Infarction has a mortality rate twice that of men (Elfre, 2004).
Regardless of these significant statistics, research on women with heart disease has been
scarce. There has been a myth that "women don't get heart disease" and in 1908, heart
disease surpassed childbirth as the largest health issue for women (Libov).
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Historically, Medical and Biological research has been based on a patriarchal system
where the male norm in research results was transferred as the norm for gender and race.
Women were not included in medical research studies because it was believed that the
female hormonal cycle would alter the research design and analysis (Greenberger, 2003).
Another concern of using women in medical research was the increase risk of birth
defects. An example of this is the use of thalidomide and DES in the 1960's and 1970's
that caused serious birth defects (Greenberger, 2003).
The lack of women being utilized in research studies was illustrated quite well in
the Harvard Physicians' Health Study that was published in 1989 (Greenberger, 2003).
This federally-funded study evaluated the benefits of taking aspirin to help reduce the
risk of having a myocardial infarction and its sample population included 22,000 men and
no women.
The Framingham Study developed a tool to determine the risk of coronary heart
disease. It uses five categories to assess risk including; age, total cholesterol levels,
HDL-C, tobacco/smoking status, hypertension (and whether the hypertension is being
treated) (Safeer, 2002). The assigned points for each of these five categories allow the
clinician to determine a patient's risk of having a significant cardiac event over the next
ten years. The initial Framingham study included men and women, however, it looked at
middle-aged people and erroneously identified men more at risk for developing heart
disease than women in early interpretations of the study (Libov). Women between the
ages of 60-64 years old who are considered at high risk for CHD were at the top 10% of
the Framingham scale and had only a 12% risk for developing CHD over a six year
follow-up. It is believed that this low probability may be inaccurate for high risk women
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because the earlier interpretations of the Framingham were taken from data on men and
included into the design of the scale (Eastwood, 2005).
In 1985, the lack of women being included in medical research was brought to
national attention through the Public Health Service Task Force on Women's Health
issues. It stated that:
"the historical lack of research focus on women's health concerns has
compromised the quality of health information available to women as well as
the health care they receive. Biomedical and behavioral research [should] be
expanded to ensure emphasis on conditions and diseases unique to, or more
prevalent in women in all age groups" (Greenberger, 2003, p. 2).

That same year, the National Institute of Health (NTH) developed new guidelines
to encourage researchers to include women in clinical research. By 1993, the FDA
reversed its policy of banning women with childbearing tendency from clinical research
and allowed them to participate in early clinical drug trials. That same year, Congress
passed the NIH Revitalization Act which established the Office of Research on Women's
Health. It requires all studies funded by the NIH to include both sexes in sufficient
numbers for a "valid analysis" (Greenberger, 2003, p.3).
Gender Differences
Current information addressing gender differences in CHD have shown that
women display anatomical differences in the structure of their hearts compared to men.
Women have smaller epicardial vessels and that the left main and anterior descending
arteries are smaller in women (Eastwood, 2005). With smaller luminal diameter of the
vessels, plaque rupture can increase risk of a total occlusion of the artery and cause a
myocardial infarction. Also, there are theories regarding differences in plaque formation
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in the coronary arteries. It is believed that women display more plaque erosion rather
than rupture which is more common in men with a Sudden Cardiac Death event
(Eastwood, 2005). Due to these differences, women present with atypical symptoms for
a myocardial infarction (MI) that can be overlooked clinically. Men tend to complain of
a crushing chest pain and show elevation in the ST segment on an Electrocardiogram
during a MI. However, women will present with complaints of burning, squeezing,
abdominal fullness, dyspnea, fatigue, nausea, dizziness, or weakness (Eastwood, 2005).
Their symptoms reflect unstable angina and usually do not show an elevation of the STsegment. Therefore, they have an increase risk of not being treated appropriately and can
increase their risk of complications since they tend to have decrease collateral blood flow
to the heart muscle (Eastwood, 2005).
Risk factors for CHD in women are similar for men in respect to hypertension,
hyperlipidemia, diabetes, and inactivity. However, diabetes has been shown to be a three
to seven-fold increase risk in women for CHD compared to men which is a two to threefold elevated risk (Eastwood, 2005). Likewise, hyperlipidemia in women greater than 65
years of age is more of a risk for CHD compared to men. For men, the important factor
that predicts risk for CHD with hyperlipidemia includes an elevated LDL-C. For women,
high levels of Triglycerides and low levels of HDL-C are predictors for increase risk of
CHD. It is believed that elevated Triglycerides can indirectly cause atherosclerosis by
lowering HDL-C and promoting small dense LDL-C (Eastwood, 2005). Elevated
Triglycerides in women can increase their risk of CHD by 75% compared to men at 30%
(Umland, 2002).
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Psychosocial factors in women have been found to increase their risk of CHD
compared to men. Depression, anxiety, and social isolation can contribute to increase
death after a MI in women. A study done in Alameda County showed that women with
less social connections who suffered an MI were three times as likely to die compared to
women who scored high on social ties (Eastwood, 2005).
Another risk factor for heart disease includes metabolic syndrome. This is
defined as a combination of conditions including diabetes, hypertension, hyperlipidemia,
obesity, and clotting abnormalities. Women are found to be more at risk for having the
combination of factors that can lead to metabolic syndrome compared to men (Knapp,
2002)
Theoretical Framework
The National Cholesterol Education Program (NCEP) was developed in the
1980's to provide guidelines for cholesterol control (Illingworth, 2003). Since then, the
NCEP guidelines have been updated with the most recent being in 2001 and referred to as
NCEP III. The purpose of the guidelines is to bring about a connection between new
trials in cholesterol management and application in the clinical setting. It is
recommended that a complete lipid profile be completed on all patients who are twenty
years or older every five years (Pasternak, 2003).
The NCEP III guidelines evaluate Total Cholesterol, Low density lipoproteins
(LDL-C), High-density lipoproteins (HDL-C), and Triglycerides. Total Cholesterol is a
sterol that is synthesized in the liver from dietary fat intake and endogenously in the cells.
It is present in all body tissues and is mainly comprised of LDL, brain and nerve cells,
cell membranes, and gallstones (Chernecky, 2004). Low density lipoproteins are
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considered the "bad cholesterol". They carry cholesterol from the liver and deposit in
the peripheral tissues, and in high levels, can be considered atherogenic (Chernecky,
2004). High density lipoproteins are considered the "good cholesterol" and is carried by
alpha-lipoprotein (Chernecky, 2004). HDL-C helps protect against CHD. Triglycerides
consist of fatty acid and glycerol ester that makes up "...(70%) of very-low-density
lipoprotein (VLDL) and a small part (<10%) of low-density lipoprotein (LDL)"
(Chernecky, 2004, p. 1093). Triglycerides are transported through the bloodstream and
the lymphatic system to adipose tissue where they are stored. They are also synthesized
in the liver and stored in adipose tissue where they may later be formed into glucose to be
used by the body (Chernecky, 2004).
LDL-C is optimal if less than lOOmg/dL, HDL-C should be above 40mg/dL, and
Triglycerides remain <150mg/dL. (See Table 1)
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Table 1.
ATP III classification ofLDL, total Cholesterol, andHDL-C (mg/dl) (Pasternak, 2003)
Cholesterol type

mg/dl

Classification

LDL

<100

Optimal

100-129

Near of above optimal

130-159

Borderline high

160-189

High

>190

Very high

Total

<200

Desirable

Cholesterol

200-239

Borderline high

>240

High

<40

Low

>60

High

HDL

The updated guidelines have also addressed those individuals who are at an
increased risk for their first coronary event. The first high risk group are those
individuals who have diabetes and a second high risk group are those individuals who
have a 10-year CHD risk >20% according to the Framingham Heart Study risk scoring
(Pasternak, 2003). (See Appendix A) The third high risk group include patients with
metabolic syndrome. According to Pasternak (2003), 3 of 5 risk factors need to be
included to identify metabolic syndrome. This includes abdominal obesity > 102cm for
men and >88cm for women, Triglyceride levels >150mg/dL, HDL-C <40mg/dL for men
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and <50mg/dL for women, blood pressure >130/85mmHg, and a fasting glucose
>110mg/dL.
Guidelines for women, according to NCEP III, suggest drug therapy if a woman
has 2 or more risk factors for CHD and a 10-year risk of 10-20% according to the
Framingham Risk tool. Women who have <10% risk over 10 years and a LDL-C level
<130mg/dL are not candidates for cholesterol lowering prescription medicine unless their
LDL-C is > 160mg/dL (Mosca, 2002).
The NCEP III guidelines have also expanded on their recommendations for
healthy lifestyle changes to help reduce cholesterol. Along with weight management and
physical activity, they have also included the use of plant stanols (2g/day) and soluble
fiber (10-24g/day) as part of the dietary regimen (Pasternak, 2003).
Plant Stanols
Plant stanols include Phytoestrogen which is a compound found in plants that are
structurally similar to estrogen and bind to estrogen receptor sites (Kris-Etherton, 2002).
Phytoestrogens display both an estrogen agonist and antagonist action and these factors
are dependent upon dietary concentrations, endogenous estrogen levels, sex, and
menopause (Kris-Etherton, 2002). Isoflavones, lignans, and coumestans are included as
phytoestrogens.
Flaxseed, a lignan, primarily contains the lignan of secoisolariciresinol (SECO)
which is considered a phenolic compound (Sterling, 2004). SECO consists of:
"...ring structures bearing attached "hydroxyl" groups. Chemically it resembles
endogenous steroid hormones. In flaxseed, SECO appears to exist as a complex
attached to two glucose (sugar) molecules-SDG. After SDG enters the intestines,
it has its two glucose molecules removed to form "aglycone" SECO" (Almada,
2003b) (See Figure 1).
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SECO and SDG are not directly absorbed into the body but are acted upon by
bacterial flora in the intestines and produces enterolactone (ENL) which then transforms
into enterodiol (END) (Almada, 2003b). Initially, these two products are derived from
plant sources, but since they are produced in the body, they are considered mammalian
lignans (Almada, 2003b). Flaxseed, a mammalian lignan has a weak estrogenic and
antiestrogenic activity comparable to isoflavones such as soy (D. J. A. Jenkins, Kendall,
C.W.C., Vidgen, E., Agarwal, S., Rao, A.V., Roseberg, R.S., et al, 1999). It is
comparable to Selective Estrogen Receptor Modulators (SERMS) by acting upon
estrogen sites (Sterling, 2004). It is hypothesized that lignans may block the activity of
progesterone receptors which would affect cardiovascular risk by changing HDL-C
metabolism (Jenkins, 1999).

Figure 1- The Biochemical structure of SECO (Almada, 2003 a)

Psyllium husk is derived from the plant Plantiago ovata that is native to Asia
(PDRfor nonprescription drugs, dietary supplements, and herbs, 2008). This is a natural
fiber that has a bulking effect in the colon that retains water in undigested fiber and
".. .increased bacterial mass following partial fiber digestion" which decreases transit
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time (PDRfor nonprescription drugs, dietary supplements, and herbs, 2008, p. 642).
In 1998 the U.S. Food and Drug Administration allowed the claim that 7gm of soluble
fiber per day can help lower cholesterol (Gamble, 2008).
Relevance to Nursing
In the health care setting, Nurses have always been on the forefront in providing
care and educating their patients. Nurses' strength has always been towards health
promotion with their patients. Historically, Nurses have looked upon their patients as a
biopsychosocial being and have tailored their approach to their patients' care as looking
at the person as a whole. Nurses have encompassed not only assessing their patients and
providing treatment for assorted disease processes, but also teaching their patients about
preventing disease and promoting a healthy lifestyle.
With the majority of the Nursing profession being female-dominated, it makes
sense that the area of preventing heart disease in women would be an area that Nurses
would want to become involved and participate in. Nurses have the ability to relate to
persons of the same gender and help guide other women to adapting healthy lifestyles.
Also, Nurses would be able to educate women about alternative, acceptable treatments to
help prevent the onset of heart disease that has been illustrated in the NCEP III
guidelines.
As there are limited studies involving postmenopausal women in relation to heart
disease and treatment, there seems to be virtually no information or research involving
perimenopausal women who may be at risk for CHD. The aim of this study is to evaluate
alternative treatments for perimenopausal women who are considered borderline
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hyperlipidemia and to see if this will benefit this particular population of women from
progressing into CHD once they have entered menopause.
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CHAPTER II
Review of the Literature
Cholesterol Treatment and Women
With CHD being so prevalent in postmenopausal women, there are limited studies
involving women in regards to heart disease and treatment. Historically, women have
either not been included in research studies for CHD or were included in small numbers
in randomized control trials (RCT) that did not crossover well to the general population
of women. Studies that were conducted to evaluate the effectiveness of the use of statins
(cholesterol-lowering medications) in preventing heart disease has been limited in
including women in their studies. (Ltd, 2005).
Women and Statins
In a study done by Ansell, et al (2005), it was recognized that there is a disparity
between men and women in regards to diagnosing and treating for early CHD. It was the
opinion that both women and physicians were unaware of the prevalence and mortality of
CHD in women (Ansell, 2006). Providers may have difficulty assessing a woman with
CHD because women present with such subtle signs that may not be directly correlated to
heart disease. This would include abdominal fullness, dyspnea, etc. Ansell, et al (2005)
identify that one in three high risk women with CHD do receive treatment, however,
physicians tend to down score the woman's risk factors to low.
The purpose of this study was to assess if there was a difference between men and
women in regards to achieving NCEP III treatment goals for lipid management. The
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study surveyed data from 376 physicians who were considered to be high volume
prescribers for cholesterol-lowering treatments. Medical information, lab data, and
therapies were included in the data that was being analyzed for the study. Of the 376
physicians, 90% were men and 42% were in Family Practice (Ansell, 2006).
The patient sample included an n=4,885 and of this number, 2,782 (51%) were
men and 2,103 (43%) were women. The age range was between 20-75 years and the
patients had been treated with a low fat/low cholesterol diet and/or medication for the last
three months. Risk factors for the patients were determined by the NCEP III guidelines.
High risk included a patient with established CHD, Diabetes, present smoker, Metabolic
Syndrome, and/or an Acute Coronary Syndrome. For women, risk factors were based on
the American Heart Association's guidelines and the Framingham Study Risk Factor. A
woman at low risk had 0-1 risk factors and < 10% risk of CHD according to
Framingham. Intermediate risk included 2+ risk factors and a 10-20% risk of CHD in the
next ten years. High risk included known CHD and risk equivalents along with >20%
risk of CHD in the next ten years (Ansell, 2006).
The results of the study showed that LDL-C achievement was equal between both
men and women with low risk (89% & 88%) and intermediate risk factors (75% & 76%)
(Ansell, 2006). However, women with high risk factors had a lower achievement of
LDL-C goals compared to men in the same risk group (50%) vs. 60%;p<0.00l) (Ansell,
2006).
In regards to management by the physician, the study showed that fewer women
were managed by a sub-specialist (Cardiologist or Endocrinologist) compared to men
(22.6%) vs. 26.8%;/?<0.001) (Ansell, 2006). There was a statistically significant finding
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in both men and women achieving cholesterol lowering goals when treated by their
primary physician and a non-significant statistic when treated by the sub-specialist.
Women in the high risk category with known CHD and Risk Equivalents had a
lower level of achieving desired LDL-C compared to men (17% vs. 18%) and also a
lower referral to a specialist compared to men (18% vs. 28%) (Ansell, 2006).
This study did identify a sub-group of women who have a high risk of CHD, yet
are not being managed as aggressively as their male counterparts in regards to referrals to
specialists or utilizing cholesterol-lowering treatments. The study did utilize a very large
percentage of male physicians (90%) and may have had a different outcome if more
female physicians or female health care providers were included in the study.
Bazian Ltd. (Ltd, 2005) performed a meta-analysis of five large cholesterol
studies to evaluate if the effectiveness of taking statin medications had a positive
outcome on cardiovascular events for women without a diagnosis of CHD. The events
that were being assessed included total mortality, CHD mortality, non-fatal MI,
revascularization, or CHD events. Included in this meta-analysis was the
AFCAPS/TexCAPS random control trials (RCT) that was performed between the years
of 1998-2001. The study evaluated the statin Lovastatin (20mg-40mg/day) vs. placebo
and a low-fat, low-cholesterol diet. Of the 6,605 participants, 997 were women. The
results showed that women alone taking Lovastatin did not show any effect on total
mortality (RR 1.53, 95% CI 0.62-3.81); CHD mortality (RR 2.99, 95% CI 0.12-73.3)
non-fatal MI (RR 0.69, 95% CI 0.21-2.28); revascularization (RR 0.87,95% CI 0.332.31); or CHD events (RR 0.55, 95% CI 0.22-1.34) (Ltd., 2005).
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The ALLHAT-LLT RCT evaluated Pravastatin (40mg/day) vs. usual care
over a 4.8 year period. The study included 10,355 participants with 5,051 of that number
being women. For both men and women, there was no difference in mortality outcome
between treatment and control groups. Yet, for women, Pravastatin did not have any
effect on total mortality (RR 0.98, 95% CI 0.83-1.17) or CHD events (RR 1.10, 95% CI
0.57-2.12) (Ltd, 2005).
The ASCOT-LLA RCT evaluated Atorvastatin lOmg vs. placebo over a 3.3 year
period. It included 10,305 participants with 1,942 being women. Results from this study
showed a lower incidence of non-fatal MI and fatal CHD in the group that was taking the
Atorvastatin (p=0.0005) (Ltd, 2005). For women who were taking the Atorvastatin, there
was no effect on CHD events (RR 1.10, 95% CI 0.57-2.12) (Ltd, 2005).
The AC APS trial was conducted between the years of 1992-1994 and had a
factorial design with four interventional groups. This consisted of lovastatin-warfarin,
lovastatin-warfarin placebo, lovastatin placebo-warfarin, and lovastatin placebo and
warfarin placebo. The length of the study was 33-36 months. There were 919
participants between the ages of 40-79 years and 441 of those participants were women.
For women alone, the lovastatin did not have any effect on total mortality (RR 0.09, 95%
CI 0.01-1.70); CHD mortality (RR 0.35, 95% CI 0.01-8.47); or non-fatal MI (RR 0.35,
95% CI 0.04-3.31)
In the HPS study, 20,536 participants were included to compare the effect of
treatment with Simvastatin 40mg/day with placebo. This study's length was five years
and included 5,082 women. Findings showed that both men and women in the treatment
groups did show significance in reduction of CHD events yet for women alone, only
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reduction in CHD events was significant (RR 0.76, 95% CI 0.62-0.94; p value not
given) (Ltd, 2005).
The meta-analysis statistics of all five studies combined showed that the use of
statins did not have any effect on total mortality (RR 0.95, 95% CI 0.62-1.46); CHD
mortality (RR 1.07, 95% CI 0.47-2.40); non-fatal MI (RR 0.61, 95% CI 0.22-1.68);
revascularization (RR 0.87, 95% CI 0.33-2.31); or CHD events (RR 0.87, 95% CI 0.691.09) in women who have not been diagnosed clinically with CHD (Ltd, 2005).
In a review article titled 'Women may not achieve same cardiovascular benefits
from statins as men "("Women may not achieve same cardiovascular benefits from statins
as men, "May 2007), a meta-analysis study was discussed that compared men and women
in relation to the benefit of decreasing CHD risk by taking statin medication. 14 RCT's
were evaluated that included a total of 54,160 men and 17,818 women. The inclusion
criteria of the RCT's had to show a comparison between statin treatment with placebo or
a routine diet with a follow-up period of 48 weeks. The meta-analysis evaluated
incidences of death, unstable angina, revascularization, MI, or stroke. Evaluating risk
factors of CHD, the results showed that a risk of greater than one of these events showed
to be significantly reduced when using a statin drug for both men and women (Men- RR
0.76; 95% CI .070-0.81 & Women- RR 0.79, 95% CI 0.69-0.90) ("Women may not
achieve same cardiovascular benefits from statins as men," May 2007). For men alone
receiving treatment, there appeared to be significant results for decrease in MI (RR-0.72;
95% CI 0.64-0.81) and a trend towards reducing mortality (RR-0.84, 95% CI 0.69-1.02)
and stroke (RR-0.91, 95% CI 0.71-1.17) ("Women may not achieve same cardiovascular
benefits from statins as men," May 2007). For women, there was a trend towards
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reduction in MI (RR-0.89, 95% CI 0.71-1.12) but no reduction in the risk of mortality
(RR-1.00, 95% CI 0.85-1.18) or stroke (RR-1.14, 95% CI 0.82-1.59) ("Women may not
achieve same cardiovascular benefits from statins as men," May 2007).
Overall, women did not show a benefit in reduction of stroke or risk of mortality
when being treated with a statin medication compared to men who did generally show
improvement. The limitation of this study was that it had a small sample size of women
to compare with men.
Research on Psyllium
Soluble fiber, such as Psyllium, has also shown to be effective in lowering
cholesterol. In the Scottish Heart Health study, dietary fiber was shown to reduce the risk
of CHD and decreased mortality while The Nurse's health study showed that 10-g/day
increase fiber intake was associated with a 20% reduction in CHD (Kris-Etherton, 2002).
A daily intake of Pysllium of 10-g/day has been shown to decrease total cholesterol by
4% and LDL-C by 7% (Kris-Etherton, 2002).
The research study done by Anderson, et al (2000) evaluated the long-term effects
and safety of taking Psyllium husk to lower cholesterol. The sample included both men
and women who had a diagnosis of hyperlipdemia. They were placed on an eight week
American Heart Association Step 1 diet and then randomized into the Psyllium (5.1gm
twice/day) or microcrystalline cellulose (insoluble fiber taken twice/day) based on the
inclusion criteria for LDL-C. Of the 459 initial participants, 200 completed the study
with the sample size of the placebo group being 39 and the Psyllium group of 161. The
treatment phase was 26 weeks.
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Results from this study showed that during the dietary adaptation phase that
included 248 participants, Cholesterol and LDL-C values decreased by 3.9% and 4.4%
respectively (J. W. Anderson, Davidson, M.H., Blonde, L., Brown, W.V., Howard, W.J.,
Ginsberg, H., Allgood, L.D., & Weingand, K.W., 2000). During the treatment phase,
Psyllium decreased total Cholesterol and LDL-C by 2.1% and 2.9% respectively while
the placebo results showed an increase of these two values at 2.6% and 3.9% (J. W.
Anderson, Davidson, M.H., Blonde, L., Brown, W.V., Howard, W.J., Ginsberg, H.,
Allgood, L.D., & Weingand, K.W., 2000). After six months of treatment, Psyllium
showed a decrease in total Cholesterol and LDL-C compared to the placebo group (4.7%
& 6.7%;p<0.001) (J. W. Anderson, Davidson, M.H., Blonde, L., Brown, W.V., Howard,
W.J., Ginsberg, H., Allgood, L.D., & Weingand, K.W., 2000). The study showed no
differences in cholesterol outcomes between men and women. Overall, both men and
women benefited in lower total Cholesterol and LDL-C values on the Psyllium (J. W.
Anderson, Davidson, M.H., Blonde, L., Brown, W.V., Howard, W.J., Ginsberg, H.,
Allgood, L.D., & Weingand, K.W., 2000).
The study did show that Psyllium was effective in lowering cholesterol over a
long period of time. However, the final sample population appeared to be not evenly
distributed in size with the placebo group being significantly smaller in number when
compared with the Psyllium group.
Anderson, et al (2000) conducted a meta-analysis of eight studies to determine the
size and consistency of Psyllium's effects on lowering cholesterol along with the safety
of its use. The sample consisted of 656 adult subjects that had a diagnosis of mild to
moderate hyperlipidemia. The participants were between the ages of 24-83 years with a
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mean age of 55.2 in the Psyllium group and 54.5 in the Placebo group (J. W.
Anderson, Allgood, L.D., Lawrence, A., Atringer, L.A., Jerdack, G.R., Hengehold, D.A.,
& Morel, J.G., 2000). There were 384 participants in the Psyllium group and 272
participants in the Placebo group. The design of the study included an eight week lead-in
with a low-fat diet phase and then continued with either taking Psyllium 10.2gm/day
along with a low fat diet vs. Placebo of taking cellulose >_eight weeks. The results
showed that Psyllium decreased total Cholesterol by 4% (pO.OOOl), LDL-C by 7%
(pO.OOOl), and the ratio of apoB to apo A-I by 6% (p<0.05) from baseline results
compared to Placebo (J. W. Anderson, Allgood, L.D., Lawrence, A., Atringer, L.A.,
Jerdack, G.R., Hengehold, D.A., & Morel, J.G., 2000). However, Psyllium did show an
increase from baseline with Triglycerides and apo A-I (p<0.05) (J. W. Anderson,
Allgood, L.D., Lawrence, A., Atringer, L.A., Jerdack, G.R., Hengehold, D.A., & Morel,
J.G., 2000). It did not show any effect on HDL-C concentrations and there were no
significant differences of Triglyceride levels between the Psyllium and Placebo groups (J.
W. Anderson, Allgood, L.D., Lawrence, A., Atringer, L.A., Jerdack, G.R., Hengehold,
D.A., & Morel, J.G., 2000).
In regards to treatment outcome differences between men and women, the
Psyllium showed a reduction of LDL-C over a eight week period for both men and
women when compared to Placebo (J. W. Anderson, Allgood, L.D., Lawrence, A.,
Atringer, L.A., Jerdack, G.R., Hengehold, D.A., & Morel, J.G., 2000).
A study done by Jenkins, et al (2002) assessed the efficacy of the dose of fiber in
reducing cholesterol values. The study consisted of 68 participants that included 37 men
and 31 postmenopausal women. The mean age of the study participants was 60 ± 1 year
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(33-82). The experimental group received a high fiber diet consisting of four servings
per day of food containing P-glucan or Psyllium 8gm/day. The control group received a
low fat/low cholesterol diet. The study was a randomized crossover study with a time
component of four weeks for each experimental or control groups. Blood pressure was
assessed as well at the baseline, two, and four week points of the study. Results showed
that a high fiber diet decreased total Cholesterol (p=0.003), HDL-C (p=0.001), LDL:HDL
ratio (p=0M5), and apo B: Apo AI (p=0.076) when compared to the control group (D. J.
A. Jenkins, Kendall, C.W.C., Vuksan, V., Vidgen, E., Parker, T., Faulkner, D., et al,
2002). There appeared to be a reduction of cardiovascular risk according to the
Framingham Study guidelines (p=0.003) and a small decrease in blood pressure for the
Psyllium group compared to the control group (D. J. A. Jenkins, Kendall, C.W.C.,
Vuksan, V., Vidgen, E., Parker, T., Faulkner, D., et al, 2002).
The study supported the claim that a diet high in fiber can lower cholesterol and
the risk of CHD. However, the study had a small sample size and for the female
population, included only post-menopausal women. Also, the design of the study only
allowed each group to be on their respective treatments for four weeks. In most
cholesterol treatment studies, data is collected over an eight week period to be able to see
significant changes.
Flaxseed Research
Lucas, et al (2001) conducted a study to examine the effects of flaxseed on lipid
metabolism in postmenopausal women who were not taking hormone replacement
medication. This double-blind randomized study included 58 women who were placed
into two groups; those taking 40gm of ground flaxseed or a wheat-based comparative
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regimen. The results of the study did show improvement of lipid levels for the women
who were taking ground flaxseed. There was a significant decrease in total cholesterol
and non-HDL-C by 6% and a non-statistical significant decrease of LDL-C by 4.7% and
triglycerides by 12.8% (Lucas, 2001). Serum apolipoprotein A-l and B were significantly
reduced by 6% and 7.5% respectively (Lucas, 2001).
Jenkins, et al (1999) research study also showed significant results in the use of
flaxseed on lowering cholesterol values. 29 participants including both men and
postmenopausal women were involved in a randomized crossover study comparing 50gm
of partially defatted flaxseed and 20gm of wheat bran that were baked into muffins. The
findings showed that partially defatted flaxseed did reduce total cholesterol (4.6%;
/?=0.001), LDL-C (7.6%;/K0.001), and apolipoprotein A-l (5.8%;/HJ.005) compared to
the control group of wheat bran (D. J. A. Jenkins, Kendall, C.W.C., Vidgen, E., Agarwal,
S., Rao, A.V., Roseberg, R.S., et al, 1999).
Both of these studies did show improvement in cholesterol values when using
flaxseed. However, the sample sizes were not large and they included only postmenopausal women in the sample.
Summary
Overall, there are limited studies involving women with heart disease and
treatment. The random controlled studies that evaluated the effects of statin drugs were
not as favorable for women as they were for men. Women who are in a high risk
category for CHD did not benefit from statin use in regards to lowering their total
Cholesterol or LDL-C values and no significant decrease in risk for an unfavorable
outcome related to CHD. Part of this may be attributed to women being scored lower for
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risk of heart disease by their physicians due to either women not understanding signs
and symptoms of heart disease or their physician being unenlightened on the subtle
differences in presentation of symptoms of CHD between the two genders.
Psyllium and Flaxseed are both phytoestrogens and, according to the
NCEP III guidelines, they can be effective in lowering cholesterol and decreasing the risk
of heart disease. However, the studies that are available have included a smaller sample
size when compared to the RCT's involving statin treatment and are only looking at
postmenopausal women and not addressing the needs for perimenopausal women who
have borderline hyperlipidemia. According to the NCEP III guidelines, perimenopausal
women with borderline hyperlipidemia would not qualify for treatment with the statin
drugs. According to the guidelines, stanols and soluble fiber would be an alternative to
help lower cholesterol levels. Therefore, could the effects of Flaxseed SDG improve
perimenopausal women's borderline hyperlipidemia when compared to Psyllium?
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CHAPTER III
Method
Sample
The sample size for this study included initially, twelve perimenopausal women
between the ages of 35-48 years with defined mild hyperlipidemia (Total cholesterol 200255mg/dL, HDL-C <50mg/dL, LDL-C 130-165mg/dL, Triglycerides 150-320mg/dL, and
VLDL >30mg/dL). The study participants met the inclusion criteria of: (1) Two out of
Five abnormal values of the lipid panel according to NCEP III guidelines, (2) a last
menstrual period (LMP) within the month of the date of entry into the study, 3) a Body
Mass Index (BMI) < 40, and (4) had a normal Complete Blood Count, Thyroid
Stimulating Hormone level, and Basic Metabolic Panel. They also met the exclusion
criteria by not having the following diseases: A diagnosis of cancer, liver disease, renal
disease, uncontrolled hypothyroidism or hyperthyroidism, gastrointestinal disorders,
Insulin Dependent Diabetes, uncontrolled Adult Onset Diabetes Mellitus Type II, a
history of Coronary Artery disease, an Arrhythmia, or taking a cholesterol-lowering
prescription medicine.
The participants were recruited from an ambulatory medical clinic in Southern
California by evaluating the clinic's database for women between the age of 35-50 years
who have an ICD-9 diagnosis of 272.4 (hyperlipidemia) on their medical charts, fit the
inclusion and exclusion criteria of the study, and once identified, discussed with their
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Provider about contacting the patient to volunteer for the study. Other methods of
recruitment included a flyer that was posted in a local gym in the same area as the clinic.
Once a potential candidate for the study was identified, permission was verbally
obtained from their Provider to contact the candidate about the study. The candidate was
then contacted through the Providers' office staff to discuss interest in participating in the
study. Once the candidate agreed, she was directed to contact the Principal Investigator
(PI) and was informed further about the study. An appointment was then set up between
the participant and the PI to enter into the study. Date, time, and location of the meeting
were made at the convenience of the participant.
At the recruitment meeting, the participant was educated in more detail about the
study in regards to the time frame of the study, the products the participant may be taking
while on the study, and the lab work schedule. Risk and benefits of the study were
discussed and written consent was obtained from the participant (See Appendix B). Also,
the participant completed a Demographic questionnaire (See Appendix C ) and the Eating
Pattern Assessment Tool (EPAT #1) (See Appendix D). The participant randomly drew a
number from a container which indicated the study group the participant would be
assigned. An odd number indicated the participant would be in the Control group of
Psyllium (Group 1) and an even number indicated the Experimental group of Flaxseed
SDG (Brevail SDG) (Group 2). The participant was then given their study product along
with verbal and written instructions on how to take the product. Also, a folder packet
was provided to the participant that included three more EPAT questionnaires to be
completed at the time of their lab draws and a copy of their informed consent. The
participants were contacted at the eight week period to meet the PI at a lab in the
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Southern California area to have their first fasting lab draw completed. At that time,
they were instructed to complete their EPAT #2 questionnaire and turn this in to the PI
when they met at the lab. The participants were given their remaining lab requisitions for
the remainder of the study and were directed to bring the appropriately marked lab
requisition with them each time they returned to the lab. One week prior to the two week
and six week washout periods, the participant was contacted by the PI by telephone to
return to the lab in one week for their fasting lab draw. The participant was also
instructed to complete EPAT #3 & EPAT #4, after each lab draw respectively, and to
mail them in the self-addressed envelope provided in their packet back to the PI.
Instruments
Cholesterol values were tested by using the VAP-II cholesterol test (See
Appendix E). The VAP measures total LDL-C-direct, total HDL-C-direct, total VLDLC-direct, Total Cholesterol, Triglycerides-direct, and total Non-HDL-C (LDL + VLDL).
It also measures Lp(a) and hsCRP. According to Atherotech, the designer of the VAP II,
direct measurement of the LDL-C rather than the Friedewald equation which evaluated
LDL-C based on measuring total cholesterol, HDL-C, and Triglycerides gives a much
more accurate look at the cholesterol values and the risk of a patient having CHD
(Paxton, 2002). It is believed that with the Friedewald cholesterol measurement, there
was a larger chance of receiving a false low LDL if the triglyceride level was high
(Paxton, 2002). VLDL-C is the main carrier for Triglycerides, and if elevated, can be a
risk for CHD (Atherotech). Non-HDL Cholesterol is the combination of LDL + VLDLC. It has shown to be a better predictor of CHD rather than LDL-C alone (Atherotech).
Lp(a) reflects a genetic risk factor for heart disease and it does not respond to the usual
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cholesterol lowering drugs (Atherotech). hsCRP is a marker for inflammatory
reactions that are occurring during an acute phase of metabolic, immunologic, or
infective processes in the body (Gotto Jr., 2006). Recent research has revealed that CRP
may be expressed from atherosclerotic lesions, coronary artery smooth muscle cells,
aortic endothelial cells, and adipocytes and CRP levels have been found to increase after
a MI event (Gotto Jr., June 29, 2006). Chronic production of CRP from atheramatous
tissue or coronary artery smooth muscle can be measured by the high-sensitive CRP
assay and this can be used to predict risk factor for a coronary event (Gotto Jr., June 29,
2006).
The VAP-II uses a "non-segmented continuous flow (controlled-dispersion)
analyzer for the enzymatic analysis of cholesterol in lipoprotein classes separated by a
short spin (47 min) single vertical ultracentrifugation" (Kulkarni, 1994). A study
comparing the Northwest Lipid Research Laboratories with the VAP-II showed a
correlation of total and lipoprotein values as well as Lp(a) with an r=0.907 (Kulkarni,
1994). The reproducibility and accuracy of the VAP-II is within the guidelines set by the
Centers for Disease Control-National Heart, Lung, and Blood Institute (Kulkarni, 1994).
Each phase of the study included an assessment of the participants' current diet
using the Eating Pattern Assessment Tool (Peters JR, 1994). The tool was developed out
of the University of Minnesota and permission to use the tool was given by the
University. The EPAT is a self-administered food questionnaire that assesses foods high
in fat and cholesterol content. It consists of two sections; the first section contains 12
questions that assesses intake of food that is considered high in fat and cholesterol.
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Section two contains 11 questions that assesses diet intake of lower fat food groupings
(See Appendix D). The goal of the tool is to:
1) Assess the overall intake of dietary fat and cholesterol; 2) assess the frequency
with which a person eats foods within each food grouping, and 3) provide an
educational message regarding types and amounts of foods that should be eaten to
achieve a nutritious, low fat diet (Peters, 1994, p. 1008).
Reliability and validity of the tool were done using repeated measures on 436
blue-collar and white-collar employees who were randomly selected and completed the
EPAT on five visits. The test-retest reliability for Section 1 and Section 2 was r>.70 over
3 time periods except for Section 2 at four months apart which was .69 (Peters JR, 1994).
The validity for Section 1 ranged from 0.55 to 0.56 across all five visits. Section 2
correlations were not as strong as Section 1 and this was believed because the food items
in Section 1 were lower in fat and cholesterol (Peters JR, 1994).
The tool has a 1-4 scoring point method and in Section 1, consumption of the
highest fat and cholesterol food items (found in column 1) is assigned a score of 4 points.
Column 2 is 3 points, Column 3 is 2 points, and Column 4 receives 1 point. Ideally, a low
score is acceptable for Section 1. Section 2, higher points are assigned to the column on
the right and encourages a higher nutritional score (Peters JR, 1994).
Data Collection Procedures
The research study data was collected by the Principal Investigator and analyzed
by a statistician. The study was a double-blind, randomized, experimental pilot study
with test and control phases. Subjects were randomized into the control Group 1 of
Psyllium 11.70gm/day and the experimental Group 2 of Brevail SDG 200mg/day.
Compliance with the study medication was evaluated by distributing the correct amount
of the product to the participants that covered the eight week period and the PI validated
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with the participants via telephone that the entire product had been taken in its entirety
as directed at the end of the eight week period. The VAPII lab was performed at week
eight and at the end of two washout periods of two weeks and one month (See Table 2).
The purpose of the washout time periods is to make sure there is no residual from the use
of the Brevail SDG or the Psyllium in order to retest lipid levels off the experimental and
control supplements. The lab work was drawn at a lab in Southern California and
shipped to Atherotech in Alabama who analyzed the VAP-II lab and returned the results
to the PI through electronic means.

Table 2
Design of the Study

GROUPS

Group 1

TIME1

TIME 2

TIME 3

WEEKS

WASHOUT

WASHOUT

1-8

2 WEEKS

4 WEEKS

Psyllium
11.70gm/day

Group 2

Brevail SDG
200mg/day

Human Subjects
At all times during the research phases of the study, human subjects were
protected under the guidelines for the expedited Investigational Review Board (IRB) as
set forth by the University of San Diego (See Appendix F). The potential risk and
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benefits of the study were discussed with the participants at the entry of the study and
informed consent was obtained. The risks to the participants were minimal and included
the potential for increase flatulence while on the study product or receiving a hematoma
from a lab draw. None of these risks were reported during the entire time of the study.
The benefit of the study was to collect data in order to identify if there was a benefit to
taking Flaxseed SDG to prevent further development of hyperlipidemia and decrease the
risk for coronary heart disease in the perimenopausal population. All information
obtained about the participants was kept private and confidential except for the reporting
of the final results.
Participation in the study was voluntary and all participants were aware that they
could withdraw from the study at any time. The research proposal was submitted and
approved prior to the initiation of the study by the University of San Diego's Human
Subjects Committee.
Data Analysis
All eleven participants who received the study products and had an acceptable
baseline measurement of Cholesterol, Complete blood count, Thyroid Stimulating
Hormone, and a Mini-Chemistry-12 panel for entry into the study were included in
efficacy analysis. The sample population was measured using descriptive frequencies to
analyze the covariate variables of age, socioeconomic status (SES), race, and BMI. Lipid
results that included a Total Cholesterol, Total HDL-Cholesterol-direct, Total LDLCholesterol-direct, Triglycerides-direct, Total Non-HDL Cholesterol, Total VLDLCholesterol-direct, Lp(a) Cholesterol, and hsCRP were analyzed at Time 1 (eight weeks
on the study product), Time 2 (two weeks off the product) and Time 3 (six weeks off the
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study product). The hypothesis that Brevail SDG will lower lipid levels in
perimenopausal women when compared to Psyllium was tested by evaluating the
continuous independent variables of Brevail SDG and Psyllium as well as the covariate
variable including the EPAT scores along with the continuous dependent variable of the
VAP-II lipid results.
This data was analyzed by the statistician using the SPSS version 15 program and
evaluating correlated t- tests to compare both groups at Time 1 vs. 2,1 vs. 3, and 2 vs. 3
for the VAP-II lab. The EPAT was evaluated by comparing sections 1 and 2 individually
at Time 1 vs. 2, 1 vs.3, 1 vs. 4, 2 vs. 3, 2 vs. 4, and 3 vs. 4. The correlated /-test was used
because it allows comparison between two groups over a period of time. It requires a
continuous dependant variable in order to allow the two groups in the experimental
design to be compared (Munro, 2005). According to Munro (2005), "In the correlated ttest, a correction is made that has the effect of increasing t, thus making it more likely to
find a significant difference if one exists" (p. 145). The purpose for using correlated /-test
for this particular study was to be able to observe for any changes in cholesterol values
during the study time points of the control and experimental groups and to be able to
compare between the two groups. Results were reported at a 2-tailed a=0.05 level.
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CHAPTER IV
Results
Description of the Sample
Of the twelve participants who entered into the study, only eleven women
completed the study. The reason for attrition of the one participant from the study was
the complaint about the taste of the product the participant was assigned to take.
The Control group (Group 1) consisted of five participants with an age range of
36-48 years with a mean of 40.65 (95%CI- 33.79/47.52) and the Experimental group
(Group 2) consisted of six participants with an age range of 36-48 years with a mean of
43.61 (95% CI- 37.92/49.29) (See Table 3). There were four Caucasians (80 %) and one
Asian (20%) in Group 1 and five Caucasians (83 %) and one Asian (17 %) in Group 2
(See Table 4). The income status in Group 1 included one participant with an annual
income between $0-$30,000 per year (20 % ); two participants with an income of
$75,001-100,000 per year (40 %); and two participants with an income >$100,00 per year
(40% ) (See Table 4 ). Group 2 had one participant with an annual income of $30,001$50,000 (17 %); two participants with an income of $50,001-$75,000
(33 %) per year; and three participants with an income >$ 100,000 (50 %) per year (See
Table 4). The BMI for Group 1 was a mean of 29.30 (95% CI-24.52/34.08) (See Table
3). The BMI for Group 2 was a mean of 29.75 (95% CI- 24.84/34.66) (See Table 3). The
/-test that was performed on both age and BMI did not show to be statistically significant
between both groups (Age-p=0.396; BMI-p=0.868) (See Table 3).
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Table 3
Descriptive frequencies for Age & BMI
AGE
GROUP
GROUP
2
1
N=5
N=6
MEAN
40.65
43.61
95% CI
UPPER BOUND
33.79
37.92
LOWER BOUND
47.52
49.29
MEDIAN
38.42
46.43
STD. DEVIATION
5.530
5.417
BMI
MEAN
95% CI
UPPER BOUND
LOWER BOUND
MEDIAN
STD. DEVIATION

GROUP
1
29.30
24.52
34.08
28.50
3.850

p-VALUE
0.396

GROUP
2
29.75

0.868

24.84
34.66
28.75
4.677

Table 4
Descriptive Frequencies for Race & SES
GROUP 1 PERCENTAGE
%

RACE:
Caucasian
Asian

4
1

80
20

1

20

SES:
$0-$30,000/year
$30,001-$50,000/year
$50,00 l-$75,000/year
$75,001-$100,000/year

2

40

>$100,000/year

2

40
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GROUP
2

PERCENTAGE
%

5
1

83
17

1
2

17
33

3

50
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The Effect of Diet
The EPAT questionnaire was analyzed showing time points (1-4) and
divided between the two sections of the questionnaire. As described in the previous
chapter, the EPAT's first section evaluates food intake that is high in fat. A lower score
on this section reflects a lower fat diet. The second section reflects a diet where healthier
choices are being made in regards to a lower fat diet. The desired results are a higher
score.
When analyzing each group for each point in time the questionnaire was
given, Section 1 showed a lower mean for time 1 & 3 (24.2/24.2) and a higher mean at
point 2 & 4 (25.8/26.6) for Group 1. Group 2 had a higher mean (27/26.67) at time 1 & 2
and a lower mean (23.83/24.67) at time 3 & 4. Section 2 for Group 1 showed a higher
mean (27.6) at time 1, but then the mean began to decrease by time 4(25.6) (See Table 5).
Meanwhile, Group 2 showed a higher mean (28.83) at time 1 with a slight decrease in the
mean value at time 2 (27.83). However, the mean value increased at both time 3 & 4
(26.67/29.33) (See Table 5).
In comparison of times, Group 1 showed an increase in negative mean differential
value throughout all four time periods for Section 1, yet none of the values were
statistically significant (See Table 6). Mean values for Section 2 also showed a decrease
in mean differential for all time points and were not statistically significant except there
was an improvement at time 3 vs. 4 with a mean differential of-0.600 and a/7-value of
0.675 (See Table 6 ).
Group 2 showed an increase in differential mean values for Section 1 throughout
the majority of time periods that were not statistically significant (See Table 6).
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However, there was a decrease in the mean differential (-0.833) with a non-statistical
p-value of 0.55 at time 3 vs. 4. Section 2 showed a decrease in differential mean value for
time 1 vs. 2 (1) and 1 vs. 3 (0.167). However, there was an improvement in differential
mean values for the remaining points in time. There was a statistically significant value
at time 2 vs. 3 (p=0.042), however, the rest of the comparative values were nonstatistically significant.

Table 5
Descriptive Frequencies ofEPAT
Brevail SPG

Psyllium
95% CI

Mean

95% CI

Mean

27
26.67
23.83
24.67

22.21/31.79
19.41/33.93
19.12/28.55
20.54 / 28.79

24.2
25.8
24.2
26.6

18.83/29.57
21.20/30.40
19.52/28.88
21.90/31.30

28.83
27.83
28.67
29.33

25.23 / 32.43
23.94/31.73
24.70 / 32.63

27.6
25.6
25
25.6

23.16/32.04
19.94/31.26
19.45/30.55
21.16/30.04

EPAT
Section 1
Time 1
Time 2
Time 3
Time 4
EPAT
Section 2
Time 1
Time 2
Time 3
Time 4

24.61
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Table 6
Correlated t-tests

ofEPAT

Brevail SDG
EPAT

Mean

Section 1

Diff.

Time 1 vs. 2
Time 1 vs. 3
Time 1 vs. 4
Time 2 vs. 3
Time 2 vs. 4
Time 3 vs. 4

0.33
3.167
2.333
2.833
2
(-0.833)

(-7.137)/7.803
(-1.906)/8.240
(-2.836) / 7.503
(-2.240) / 7.906
(-4.537) / 8.537
(-4.179)/2.513

1
0.167
(-0.500)
(-0.833)
(-1.500)
(-0.667)

(-1.737)/3.737
(-2.905) / 3.238
(-4.468) / 3.468
(-1.623)/(-0.043)
(-3.676) / 0.676
(-2.834)/1.501

CI 95%

Psyllium
p-Value

p-Value

CI 95%

0.913
0.169
0.298
0.211
0.467
0.55

Mean
Diff.
(-1.600)
0
(-2.40)
1.6
(-0.800)
(-2.400)

(-7.594 / 4.395
(-4.390)/4.390
(-8.263) / 3.463
(-0.656) / 3.856
(-4.014)/2.414
(-5.977)/1.177

0.5
1
0.319
0.12
0.528
0.136

0.391
0.895
0.759
0.042*
0.137
0.465

2
2.6
2
0.6
0
(-0.600)

(-1.166)/5.166
(-0.517)/5.717
(-2.118/6.118
(-0.816)/2.016
(-2.776) / 2.776
(-4.283) / 3.083

0.154
0.081
0.249
0.305
1
0.675

EPAT
Section 2
Time 1 vs. 2
Time 1 vs. 3
Time 1 vs. 4
Time 2 vs. 3
Time 2 vs. 4
Time 3 vs. 4

VAP-II Results
Psyllium Group
The descriptive frequencies of all the VAP-II results evaluate mean values in each
time point on the study. Total Cholesterol, LDL-C, and Non-HDL-C showed an increase
in mean value from Time 1 to Time 3 (See Table 7). Whereas, HDL-C, Triglycerides,
VLDL-C, Lp(a), and hsCRP improved their mean values from Time 1 to Time 3 (See
Table 7).
The comparison of time points evaluated the results from the different phases of
the study. Total Cholesterol, LDL-C, Non-HDL-C, and hsCRP mean differential values
became an increasingly negative value between Time points 1 vs. 2; 2 vs. 3; and 1 vs.3
However, there was no statistical significance (See Table 8). Whereas, HDL-C,
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Triglycerides, VLDL-C, and Lp(a) showed improvements in the differential mean
values between Time 2 vs. 3 and 1 vs. 3 (See Table 8 ). However, VLDL-C was
statistically significant at Time 1 vs. 3 (p=0.021) and a very close statistically significant
value for Triglycerides at Time 1 vs. 3 (p=.055). Otherwise, the other values were not
statistically significant.
Brevail SDG Group
Evaluating the descriptive frequencies of individual time points for the Brevail
SDG, Total Cholesterol and LDL-C had a slight increase in mean values between Time 1
& 3 (See Table 7). HDL-C showed a slight increase in mean value between Time 1 & 3
which reflects an improvement of HDL-C value (See Table 7). Triglycerides, VLDL-C,
Non-HDL-C, Lp(a), and hsCRP showed an increase in mean value from Time 1 to Time
2, yet a decrease in mean value from Time 1 to Time 3 (See Table 7).
In the comparison of time points, hsCRP and Lp(a) showed an increase in
negative differential mean values from Time 1 vs. 3 with an even greater increase in
negative differential mean values from Time 2 vs. 3 though there was no statistical
significance. LDL-C also showed an increase in negative differential means throughout
all time points, yet, there was no statistical significance (See Table 8). Total Cholesterol,
HDL-C, Triglycerides, VLDL-C, and Non-HDL-C showed an increase negative mean
differential at Time 1 vs. 2 with an improvement in the differential mean values at Time 1
vs. 3 and 2 vs. 3. However, for Total Cholesterol, HDL-C, and Non-HDL-C there was no
statistical significance (See Table 8).
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Statistically significant values were observed with the Triglyceride level at
Time 1 vs. 2 (p=0.043) and Time 2 vs. 3 (p=0.047). Also, the VLDL-C was statistically
significant at all time comparison points (p=.047/0.031/0.011) (See Table 8).
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Table 7
Descriptive Frequencies ofBrevail SDG & Psyllium VAP- II results
Psyllium

Brevail S D G

Total Cholesterol
Time 1
Time 2
Time 3
LDL-C
Time 1
Time 2
Time 3
HDL-C
Time 1
Time 2
Time 3
Triglycerides
Time 1
Time 2
Time 3
VLDL
Time 1
Time 2
Time 3
Non-HDL-C
Time 1
Time 2
Time 3
Lp(a)
Time 1
Time 2
Time 3
hsCRP
Time 1
Time 2
Time 3

Mean

95%CI

Mean

95%CI

222.83
228.67
224.33

194.66/251
195.50/261.84
192.70/255.97

230.6
227.8
231.8

200.11/261.09
199.95/255.65
201.47/262.13

149
149.5
151.33

123.22/174.78
124.17/174.83
124.21/178.45

147.2
147.2
152

119.92/174.48
122.91/171.49
127.09/176.91

49.33
51
51.33

36.38/62.28
37.88/64.12
35.77/66.89

54.2
52.6
55.4

31.11/77.29
31.30/73.90
31.80/79.00

151.33
166.5
130.83

90.23/212.44
104.10/228.90
81.19/180.48

177
175.6
155.4

96.48 / 257.52
51.94/299.26
73.73/237.07

26.5
30
24

24.45/28.55
22.10/37.90
20.56 / 27.44

28.4
28.2
24.8

18.56/38.24
17.01/39.39
15.83/33.77

174.17
178.17
173

145.80/202.53
146.53/209.80
142.30/203.70

175.6
175.4
176.8

155/196.20
155.44/195.36
154.84/198.76

9.67
9.5
10.33

2.23/17.11
3.96/15.04
4.83/15.83

11.2
11.4
9.4

2.19/20.21
(-0.63) / 23.43
(-0.75)/19.55

4.433
3.917
11.367

1.015/7.852
1.021 /6.812
(-9.085)/31.818

4.94
3.06
3.88

(-5.257)/15.137
(-2.32) / 8.441
(-2.047) / 9.807

*p<0.05

39

40

Table 8
Correlated t-testsfor Brevail SDG & Psyllium VAP-II results
Psyllium

Brevail SDG
Mean

95% CI

p-Value

Differential

Mean

95% CI

p-Value

Differential

Total Cholesterol
Time 1 vs. 2

-5.833

(-26.349)/14.682

0.498

2.8

(-11.259)/16.859

0.61

Time 1 vs. 3

-1.5

(-15.147)/12.147

0.789

-1.2

(-24.386)/21.986

0.893

Time 2 vs. 3

4.33

(-16.568)/25.234

0.617

-4

(-21.183)/13.183

0.563

Time 1 vs. 2

-0.5

(-21.179)/20.179

0.953

0

(-18.892)/18.892

1

Time 1 vs. 3

-2.333

(-12.215)/7.548

0.57

-4.8

(-24.771)/15.171

0.541

Time 2 vs. 3

-1.833

(-17.727)/14.060

0.779

-4.8

(-18.185)/8.585

0.376

Time 1 vs. 2

-1.667

(-6.297) / 2.964

0.397

1.6

(-3.712)/6.912

0.45

Time 1 vs. 3

-2

(-7.473) / 3.473

0.391

-1.2

(-7.371)/4.971

0.618

Time 2 vs. 3

-0.333

(-8.121)/7.454

0.917

-2.8

(-7.561)/1.961

0.178

Time 1 vs. 2

-15.167

(-29.577) / (-0.756)

0.043*

1.4

(-112.51)/115.311

0.974

Time 1 vs. 3

20.5

(-12.824)/53.824

0.175

21.6

(-0.778)/43.978

0.055

Time 2 vs. 3

35.667

0.781 / 70.553

0.047*

20.2

(-85.529)/125.929

0.625

Time 1 vs. 2

-3.5

(-6.933) / (-0.067

0.047*

0.2

(-8.856) / 9.256

0.954

Time 1 vs. 3

3.5

0.477 / 6.523

0.031*

3.6

0.880 / 6.320

0.021*

Time 2 vs. 3

7

2.450/11.550

0.011*

3.4

(-7.011)/13.811

0.416

Time 1 vs. 2

-4

(-26.819)/18.819

0.671

0.2

(-11.295)/11.695

0.964

Time 1 vs. 3

1.167

(-8.952)/11.285

0.779

-1.2

(-21.591)/19.191

0.878

Time 2 vs. 3

5.167

(-14.426)/24.760

0.528

-1.4

(-16.898)/14.098

0.814

Time 1 vs. 2

0.167

(-3.045) / 3.378

0.899

-0.2

(-3.862) / 3.462

0.887

Time 1 vs. 3

-0.667

(-3.963) / 2.630

0.625

1.8

(-2.067) / 5.667

0.266

Time 2 vs. 3

-0.833

(-2.870)/1.203

0.341

2

(-1.926)/5.926

0.23

Time 1 vs. 2

0.5167

(-1.3051)/2.3385

0.499

1.88

(-2.9564/6.7164

0.341

Time 1 vs. 3

-6.9333

(-26.5976)/12.7309

0.406

1.06

(-4.0615)/6.1815

0.596

Time 2 vs. 3

-7.45

(-25.8364)/10.9364

0.345

-0.82

(-2.6372) / 0.9972

0.279

LDL-C

HDL-C

Triglycerides

VLDL

Non-HDL-C

Lp(a)

hsCRP

VO.05
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CHAPTER V
Discussion
The purpose of this study is to determine if Flaxseed SDG would have an effect
on lowering cholesterol levels in perimenopausal women with mild hyperlipidemia. An
experimental, pilot, randomized, double-blind study of 11 perimenopausal women was
utilized to determine the results. Though the sample size was small, and did not yield a
robust study, there were some significant findings and trends for both groups.
Synopsis ofBrevail SDG Results
The Brevail SDG group did show significant findings for the VLDL cholesteroldirect during all three time points of the study. The VLDL-C did show a higher mean
value at the two week washout period but then decreased in value by Time 3 and an
overall improvement between the two and six week washout period. Likewise, the
Triglyceride level was statistically significant showing an increase in Triglyceride at the
two week washout period and then decreasing dramatically at the six week washout
period when compared to the mean value of Time 2. Once again, the overall change in
value improved six weeks off the product. According to Barlean's Organic Oils, Inc. the
manufacturer ofBrevail SDG, the half-life ofBrevail SDG is ten hours. Therefore, it
cannot be supported that the flaxseed product influenced the improvement of the VLDL
cholesterol-direct and Triglyceride levels at the six week washout period when the
participants had been off the product.
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There was a trend for improvement of values for Total Cholesterol, HDL-C,
and Non-HDL-C at the six week washout period when compared to the mean values of
being on the Brevail SDG. LDL-C, Lp(a), and hsCRP appeared to have a more favorable
differential mean value while on the Brevail SDG compared to being off the product at
the six week washout period. In regards to the hsCRP, there was an outlier at the six
week washout period. The participant's hsCRP at baseline was 29mg/L; time 1 was
5.80mg/L ; time 2 at 7.70mg/L. At the six week washout period, her hsCRP increased to
50.90mg/L. However, there was no statistical significance at all time points for hsCRP.
Synopsis of Psyllium Results
The Psyllium group showed statistical significance for improvement of VLDL-C
levels between being on the Psyllium compared to six weeks off the product. The Total
Cholesterol, LDL-C, Non-HDL-C, and hsCRP showed a trend for improvement in values
when on the Psyllium compared to being off the product for six weeks. HDL-C,
Triglycerides, VLDL-C, and Lp(a) appeared to have a trend of improvement six weeks
off the product rather than being on the Psyllium.
Brevail SDG vs. Psyllium
Comparing Brevail SDG and Psyllium together, both of their values for HDL-C,
Triglycerides, and VLDL-C seemed to improve at the six week washout period compared
to being on their respective products. However, the VLDL-C was only statistically
significant for the Brevail SDG during all time points and for the Psyllium at time 1 vs. 3.
Ironically, Lp(a) increased in value off the Brevail SDG and decreased in value on the
Psyllium at the six week washout period. Therefore, though non-statistically significant
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for both, Lp(a) appeared to respond favorably when taking Brevail SDG rather than
Psyllium.
The findings of the EPAT tool were non-significant for the Psyllium group and
were statistically significant for the Brevail SDG group for Section 2 at time 2 vs. 3.
Overall, according to the analysis, diet did not seem to influence the outcome of the
cholesterol values for either group.
In the study performed by Lucas, et al (Lucas, 2001) involving 58
postmenopausal women who took grounded flaxseed, it showed a significant decrease in
total cholesterol and non-HDL-C values which the present study did not repeat.
However, with the present study, there were non-statistical significant changes with an
improvement of the HDL-C at the six week washout period with the flaxseed. Also,
Lucas, et al (2001) study showed non-statistical decreases in LDL-C, Triglycerides, and
Serum apolipoprotein A-l and B. The current study also repeated non-statistical findings
for decreasing LDL-C and Lp(a) while on the Brevail SDG, yet showed significant values
of changes over time with the Triglycerides for increasing at the second week washout
period and then decreasing by the sixth week washout period.
Jenkins, et al study (1999) that included 29 participants of both men and
postmenopausal women who were taking either 50gm of partially grounded flaxseed or
20gm of wheat bran showed with the flaxseed group significant findings for reduction of
total Cholesterol, LDL-C, and Lp(a). As mentioned, there were non-significant statistics
that showed lower values for these same components while on the Brevail SDG
compared to the six week washout period.
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While the original hypothesis that Flaxseed SDG would have an effect on lipid
levels in perimenopausal women with mild hyperlipidemia was not supported, there were
significant findings with the VLDL-C and Triglycerides that could have been affected
indirectly by the flaxseed, though those mechanisms are unknown at this time. Also, even
though non-statistically significant, there appeared to be a slight improvement of Total
Cholesterol, LDL-C, and Lp(a) while on the Brevail SDG. Based on these findings, there
seems to be sufficient evidence to support repeating this study on a larger basis to
determine if there truly is an improvement of cholesterol values while taking Brevail
SDG.
The limitations of this study included the small sample size, not including the
element of exercise as a covariate that could potentially affect the cholesterol levels, and
not utilizing the entry- into- study baseline lipid panel results for comparison with the
lipid results throughout the study. The entry-into-study baseline labs were, for some
participants, almost a year old before the study began and may or may not have reflected
the true values of their cholesterol panel when the study began. When the data analysis
was originally computed including the baseline lab, it tended to skew the results from the
study and did not portray a realistic look at changes from being on the products and the
two washout periods. Also, for most of the participants, their initial baseline lipid panels
did not include all of the components found on the VAP-II lab that were included in the
study, and therefore, it could not provide a true comparison of pre- and post-test results.
Recommendations for this study would include repeating the study using a larger
sample size and extending the time phase of being on the study products. This would
allow for a more robust study and to allow for a more realistic analysis of determining if
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there was a significant difference of lowering cholesterol levels while taking Brevail
SDG. Interestingly, both Brevail SDG and Psyllium showed significantly improved
values of VLDL-C and Triglycerides at the six week washout point. It may be
advantageous to evaluate urine metabolites throughout the study to determine absorption
and excretion of the Brevail SDG in order to be able to explain why there was a trend for
improvement in the majority of the cholesterol values at the six week washout period and
to see if this product did influence its effect.
Also, exercise would be another independent variable to evaluate in the study.
This was not included in the present study and could have shown to be a factor that may
have influenced cholesterol results. Another recommendation would be to perform a
VAP-II lab test at the onset of the study and to be able to compare pre-study cholesterol
values with the experimental lab values as well as the two washout periods. This would
allow for a more complete view of potential changes in cholesterol values during all time
points of the study.
Implications for Nursing
Nursing, as a profession, contributes to health care by educating their patients
about preventative health, and by doing this, allows their patients to choose behaviors
that would lead to healthier lifestyles. This particular study fits in quite well with this
philosophy of Nursing by focusing on prevention and evaluating alternative methods of
treatment for hyperlipidemia in perimenopausal women in order to prevent them from
progressing into CHD once they become menopausal.
It is very important that Nursing become more involved in research in the area of
preventative health and evaluating alternative treatments for particular disease processes.
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By becoming more proactive in this area of health care, Nurses can take their research
findings, apply the findings, and continue to promote and educate their patients about
disease prevention. In regards to women's health, it is also imperative that Nursing
become more active in conducting research studies since the majority of Nurses are
women. Historically, women have not been utilized in research studies. However, that
trend has been changing since the 1990's where legislation has encouraged including
more women in health care research. It would behoove Nurses to become more involved
in developing and implementing research studies that focuses primarily on the unique
health care needs of women. By doing this, Nurses can follow their underlying
philosophy of caring for an individual as a biopsychosocial being and continue to
promote preventative health care in order to decrease the number of individuals who end
up with major disease processes.
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CONCLUSION
Heart disease is the number one cause of death in women and those numbers may
be on the rise. 500,000 American women are dying from heart disease every year and
have a higher incidence of metabolic syndrome and diabetes when compared to men.
Scientific research is now acknowledging that women are anatomically different in
structure of the coronary arteries and present with different symptoms of an MI when
compared to men.
Historically, women were treated the same as men in regards to assessment and
treatment of CHD. Earlier research for treatment of heart disease excluded women
because it was believed that their hormonal changes may influence the outcome of the
studies. Also, there was concern of utilizing women of childbearing years in the studies
for fear of causing birth defects. Within the last 15 years, this philosophy has been
reversed and we are now seeing more studies including women. However, in regards to
treatment of women with statins for lowering cholesterol, there appears to be some
question if women receive the same benefit as men in lowering their cholesterol.
The NCEP III guidelines addresses gender differences in their recommendations
and are now including special circumstances for women who may be at risk for CHD in
regards to treatment for hyperlipidemia. Women with a low-risk score and mild
hyperlipidemia, who are not candidates for statin medications, may benefit not only from
a low-fat diet and exercise, but also utilizing plant stanols or soluble fiber in the diet to
help decrease cholesterol.
Flaxseed is part of the Phytoestrogen category of stanols and is a mammalian
lignan that has a weak estrogenic and antiestrogenic activity. It has been compared to a
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Selective Estrogen Receptor Modulators (SERMS). Studies that have been performed
evaluating flaxseed for lowering cholesterol have been limited and included only
postmenopausal women. There have been no studies identified in the literature that
addresses perimenopausal women with mild hyperlipidemia in regards to prevention of
developing CHD utilizing flaxseed.
This experimental, pilot study evaluated 11 perimenopausal women to determine
if Flaxseed SDG (Brevail SDG) could lower cholesterol levels when compared to
Psyllium. The results showed a significant value of improving VLDL-Cholesterol Direct
over all 3 time points of the study and an improvement of the Triglyceride level at the six
week washout period. Otherwise, there were favorable trends in improvement of LDL-C,
hsCRP, and Lp(a) while on the Brevail SDG.
Based on these results, it could be supported that there is a need to repeat this
study utilizing a larger sample size of perimenopausal women with mild hyperlipidemia
in order to determine if flaxseed would benefit in lowering cholesterol. By repeating this
study, hopefully, it can allow us to support the use of lignans as a preventative treatment
in this particular population who may not qualify for standard cholesterol medication
treatment. In time, it may help prevent women from furthering their risk of developing
CHD and help to decrease the morbidity and mortality of this prevalent disease in
women.
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APPENDICES
APPENDIX A - FRAMINGHAM GLOBAL RISK SCORING
Estimate of 10-Year Risk for Men
(Framingham Point Scores)
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SO-59 y
0
3

Age
60-63 y
0
1

&60
50-*»
40-49
<40

P o i n t Ttrtal
<0
0
1
2
3
4
5
6
7
8
S
10
11
12
13
14
15
18
ai7

0
1

Points
~1
0
1
2

HDL,mg/dt.

Systolic i3P,
ttwHg
<120
120-128
130-139
140-159
sEieo

Age
70-7S y

H Untreated

If Treated
0
1
2
2
3

0
0
1
1
2
10-Year fRis*;,%
<:1
1
1
1
1
1
2
2
3
4

s6
8
10
12
18
20
25
Ss30
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Estimate of 10-Year Risk for Women
IFramingham Point Scores)
_«8?,y

points

lo-I*"
36-39

_

-3
0
3
6
8
10
12
14

40-44
45-43
5Q-5*
6S-S9
80-64
65-69
70-74

_i8 .

J 5 i 2 _ ™ _ . ._

Points
Tottf
Cholesterol,
R«ML

c"

—— -

Age
20-39 y

Age
40-49 y

0
4
8
11
13

0
3
6
8
10

<ieo
180-139
200-2®
240-278
£280

Age
50-«9y
0
2
4
5
7

Age
eo-69y
0
1
2
3
4

1
Age
70-78 y
0
1
1
2
2

Points

NoRsmoNer
Smater

r——
Age
20-39 y
0
8

Age
40-49 y
0
7

Age
50-59 y

Age
80-69 y

Aee '
70-79 y

0
4

0
2

0
1

HDL,mg/dL

Points

"'gg*™'™'
50-S9
40-48
<40

......

_

O
1
2

Sysrtofe BP, m m H g

tf untreated

If Treated

<iao

0
1
2
3
4

0
3
4
5
6

133-129
130-138
140-158
aieo
Point TOW

10-Year Risk, %

<9
8
10
11
12
13
14
15
18
17
18
19
20
21
22
23
24
S2S

<1
1
1
1
1
2
2

a

4
5
6
8
11
14
17
22
27
a30
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APPENDIX B - PARTICIPANT CONSENT
RESEARCH PARTICIPANT CONSENT FORM
The Effects of Flaxseed SDG on Lipid Levels in Perimenopausal Women with Mild
Hyperlipidemia
Bonnie Marblestone, RN, Ph.D-c, CFNP is a doctoral student in nursing at the
Hahn School of Nursing and Health Science at the University of San Diego. You are
invited to participate in a research project she is conducting to study the effects of eating
Flaxseed SDG (a naturally occurring grain) on the levels of fats (like cholesterol) in your
blood. If you decide to be in the study, here is what will happen:
After reading this consent form and asking Bonnie any questions you have,
Bonnie will ask you to sign this form and keep a copy for yourself. Then she will ask you
to pick a random number out of a hat. Depending on the number you pick, you will be
given either a package of Flaxseed SDG OR a package of Psyllium. Both of these are
naturally occurring grain fiber. You won't know which one you are getting. Bonnie wants
to find out if the flaxseed works better than Psyllium in lowering your cholesterol levels.
Both of these grain fibers have the potential to give you some side effects. The most
common side effect of both of these grain fibers is that you may be passing more gas. If
this becomes a problem for you, please contact Bonnie right away and she will give you
some Beano, which is a naturally occurring substance that helps prevent gas formation. If
at any time you notice distressing symptoms like abdominal pain or bloating, chest pain,

or trouble breathing, stop taking the grain fiber and immediately seek medical help.
Bonnie will give you written instructions about how much grain fiber to take and when to
take it. Depending on which kind of grain fiber you get, you will be taking about either a
56
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tablespoon or a teaspoonful once a day, every day, for 8 weeks. Bonnie will then help
you fill out a form that asks about your age, race, and annual income, and another form
that asks you to circle the kinds of foods you've eaten in the past week. This first meeting
with Bonnie will take about 60 minutes.
Bonnie will call you to set up 3 more meetings with you. The meetings will
happen 8, 10, and 14 weeks after your first meeting. You don't have to worry about
keeping track of these times, though, because Bonnie will call to remind you. At each
meeting, you will meet Bonnie at a convenient time and place for you. Bonnie will be
happy to spend time with you if you have any questions about the study. Then she will
ask you to fill out a form asking about the foods you've eaten in the past week. She will
then go with you to have your blood drawn. Each of these 3 meetings will take about 30
minutes.
About the blood sampling: You will be asked to provide a 10 ml blood sample (about a
teaspoon) 3 separate times: these meetings with Bonnie will occur 8,10, and 14 weeks
later. A licensed person called a venipuncturist will draw your blood at the Pomerado
Hospital lab service. The procedure will use all sterile equipment. You may feel a slight
pinch as the blood is being drawn. This will last about 5 seconds. Most people have no
problems with their blood being drawn, but in rare instances they do feel faint. Bonnie
will be with you during it and will stay with you 10 minutes after it is done. If you feel
dizzy or funny at all, please tell Bonnie right away. If you get a red, swollen place where
the blood was drawn later in the day, call Bonnie right away.
Participation is in this study is entirely voluntary. You don't have to do this, and
you can refuse to answer any question and/or quit at any time. Should you choose to
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quit, no one will be upset with you and your information will be destroyed right away.
If you decide to quit, nothing will change about the way doctors and nurses care for you.
The information you give will be analyzed and studied in a manner that protects
your identity. That means that a code number will be used and that your real name will
not appear on any of the study materials. All information you provide will remain
confidential and locked in a file cabinet in the researcher's office for a minimum of five
years before being destroyed.
The benefit to participating will be in knowing that you helped health care
providers learn how to better help women lower their cholesterol levels.

If you have any questions about this research, please contact Bonnie Marblestone at 619987-8098 or Dr. Jane Georges at the University of San Diego at 619-260-4548.
I have read and understand this form, and consent to the research it describes to
me. I have received a copy of this consent form for my records.

Signature of Participant

Date

Name of Participant (Printed)

Signature of Investigator

Date
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APPENDIX C - DEMOGRAPHIC QUESTIONAIRE
DEMOGRAPHIC DATA

AGE:

CODE

RACE

INCOME PER YEAR
(Check appropriate line)
$0-$30,000
$30,001-$50,000
$50,001-$75,000
$75,001-$100,000
>$100,000

BMI
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APPENDIX D - EATING PATTERN ASSESSMENT TOOL (EPAT)

•DIBECTIONSH o w t o c o m p l e t e E P A T : For each of the 23 food
groups on the chart, circle o u t box to the right of each food
group that best describes your usual eating habits The
correct answer is what you actually eat If you have
trouble choosing between two boxes, circle the one that
comes closest
H o w m u c h i s a s e r v i n g ? Use the serving sizes
listed next to the foods to determine the number of
servings you eat Hlntt One "serving* is not necessarily
the amount you eat at one sitting If you eat a whole pizza,
that's 4 servings, not t .

A d r J i n g i t a l l u p : You probably eat a variety ol foods
within each food group. Include the listed foods you eat
plus other similar items when you estimate the number
of servings.
For example: In an average week, Joe might eat four
pancakes for breakfast one weekend morning (4 pancakes =
2 servings). During the week, he has a doughnut at his coffee
break about three times a week (3 doughnuts - 3 servings)
He seldom eats desserts, but may snack on a farge cookie
about once a week {t targecookie- 1 serving). That adds up
to 6 servings in the Baked Goods group. (See the example
below)

FOOD GROUPS AND SERVING SIZES

Baked Goods such as:
Doughnuts, sweet foils, muffins 1 avg.
1«vg t piece
Cakes, coffee «ake$
Cooktee2 avg or 1 large
Pie
i avg wedge
Granoia bars
tfoar
Granoia csreafs
V2oup
Pancakes
2avg
Waffles, feenqh to,»st
t avg-

1|§|M

Remember breakfast snacks, and coffee breaks!
7 o f more
servings pet^Weefc ,

3*4 ^servsigs^

"£ or !ea«
servings per v

SG

Never eat

SECTION I f B l i

PLEASE BEGIN HERE:
FOOD CROUPS

SND SERVING

CIRCLE ONE BOX FOR EACH FOOD GROUP

SIZES

• CciiJcnictre Foods I.LC.I ae
I

1 i* i P f * TTti It HdriCWr C*1

L

A, ( q i i l C

lltl

;

U

j

U 'III i t / •»"•'

j

rn„ i I V

S

i\ i p 15 r i*

* SMT.V-T.KT

* or more
••* rvtngs per weak

]. *; *\ C| ' C.2* 1

(il*H.--iJTJili 1 1 111 t
.jf 'l _ h / / _,

..IK1 iJ •• Sit*

3-6 servings
per week

1-2 servings
per week

1'4 IIH-ll p . -,i
1 C-l|)
•

Less than 1
serving per week
or
Never eat

CF

i n pi* p »

j , 1 * , Mr* i - ' i iQ's Aftiifi f"Vli.ir '/J

• p n c ^ s s e d Ho»ts and
j l T i l r l m m t ^ Red ModtS iucr. as
i t tji 1 " <ii in il
2 tl t«c
1 \ ti-'O'i h'l'j'us* * JS-X)|J 1 a»j
liiiiliwursi
1 lirrk
'*•».»
-i

3-S servings
per week

1-2 servings
per week

Less than 1
serving per week
or
Never eat

" ! iys eat poultry
» i h skin

Usually eat poultry
with skin

Usually aat poultry
without skin

Always eat poultry
without skin
or
Never eat poultry

UN

• I'I_-P|

f jml

*nh

C o r more
viMngs per week

i

i IHU,O

i*jrf<.i
Lit

1 iin'i

'«.p«'

' i ii i LI

»•»

!
1

JfoncHitrus&OHLY
' i i 1 i it-Tjuriin oi in«* I IIJ ui i j »f K riii»a((

W-4

X-3

*
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r»2

Z-1^~~^

PS
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FOOD GROUPS AKB SERVISS SIZES

Eggs

1 whofeagg

used so baking)

(Most athef dairy desserts are m Section iL)

Dairy Foods such as:. "
See cream

CIRCLE OME BOX FOB EACH FOOD GROUP
6 or more
whoie eggs

S-S eggs
per weak

2-8 eggs
per week

Z or mors
servings per *

i»3 sewings

Less than i

3-8 savings
per week

1-2 servings
per week

S-4 saatngs

i serving

Usua% use
Sard, cream.

margarine, salad

or eat only ogg

V2 oip or i scoop

{%fcs! ofter rnjte and yogurts- srs *? Seetfou ft/
? or m o w
Whole m i *
servings per i
» t r *
•
1 cup .
Fteguiar jWgvrt

(fl&st otfter chesses me In Secttkxr II.)

Cheeses such as;
Don't forget cheese contained'te misted: dishes, S « f a»«ra
e.g., sauces, cheeseburgers, pizza and servings per *
blue cheese dressing.
Cheddar, Colby
1 oz. site®
American, processed cheese! oz sfce

Types os Fats aftdi Oils Used'
fln cooking and at t i e table, but not ta baHed •
goods)
include cream and fat used in 1
wefl 3s spread oh breads, ete.

ofc, or
Never use
any fats or oils

Amount of vtsiMe Fats and Otis
Do net include fats arid oils used in cooking
or baking here. Do tedude iats such as:
Butter, margarine, teal ' 1 &aspo«v
(as a spiead or en
( I pa?)

vegetables, ete.J
1 T#fespoon
(rraryonnaise, french, eta.)
Cream
1
(whipped, sow, half and
half, or cream substtlutes)
Peanut butter
i °fs
Muts, seeds (stoned)
'1 T*

Baked Goods such as:
Doughnuts; sweet roils,.:

Cookies.
Pie

Snacic§ such as

1 Svg.'
1 av0, piece
Z avg. or 1
1 svg, wedge
J bar.1«cup ,
•2avg,
,1 avg.

S n a * erectors
Chips

12)
12 chips
1 small or

ChcWate candy

£ ox. or 1 avg.

gm^ftc&sB oMtv

S servings
per day

6 Of ware
servings
per day

4.
per day

3 or tees
servings per day

Mote: These servings are tfgilX amounts, not weekly.

Remember breakfast, snacks, and cojfee breaks!
7 or i
sewings per *

2 or less
servings per s

7 or mors
servings
per week

2-6 servings

Rarely o r r

3 o r KK*fe
servings per ^

£ servings per week: 1 serving per week

Rarefy or never eat I

W-4

X-3-
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Y-2

Z-1

CIRCLE ONE B O X

TOOD GROUPS AND SERVING SIZES
Trimmed Red Mea»~such as: v
Luw-fatfurKh m e *
• 2 sfess
{s.g.S5% fat-free) ' .<.
^v
PorMKKiMairij.veBi ,- 1«s«d. slice or'
1 med.ehop
, t/4-oouisd "> „

Peuifry and F»s&/Seafoo$ -,
soc&as:
• -...
-^
.'"

sawing pw week
fi-7 servings

TB

7-8 servings
per week

^PF

A*
dngs
par week
2 or
s©
or

Turkoy lunch mesJ ,

i aug, piece or
OS cup (Seed
Zsfcss

HsHMteS

ln*d

Tuns

Vitamer

.
Qssjj ' -

FOB EACH F O O D SROUP •

^

-

5 4 servings

3-4 S8n*igs
per week

,#V
10 or
BBC^ servings

s

• ttZsvg.cars
., 1/2cupOf2togs

"•

Cairjf Foods such as:

2 servings

1/2oup'
•

8oft-sav« .,
lyogurt-

iiyi

N of.'.'
' ^ 1 SCOGO

Sim

^la**fet or non-fat yo@drt
C f t e e s e a such as,' .
Don't tonjef ehaes* contained in
mastf dtehes,e g., s
- I'OXslfeSB
•UtaCottsga cheese, ikstta

' 1oi.*e

if

1-2

;3-4 servings
per week

1-2 servings

3-5 servings
perweefe

5-6 servings

CL

*

..1/4 cup

_ such as; ,
Kidney beans, lima team,. 1/? eup cooked
split peas, or other dried
beans or dried peas '
Preparation Method for. Meat,
f i s h apej Poultry
Fried or cooked \»itn 1st
(Jsutter, raargannsv 08,
shortening oi Sam)-,.
-. -

[Preparation Method
iBafceef Ge«te

K)BOF?SCEUS£0Nt¥

senitngper*
or

with fat or
commercial
breading

Usually prepared
wHhfator

without fat or
commercial

BN
fetor
rdal
brsatSng, or

PM

ifeh or poultry
Eat both eommsrtaaiiy prepared and

tor,

W-1-

•x-a
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Usually sat home-

PB
Y-3'

Z-4
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Note: the serwfngs below nr© daily amounts, net vimkly.
FOOD CROUPS Am s&mma aizss

jf—

CIHCLE ONE BOX FOR EACH FOOD GROUP
1

Breads: end'Otlnw Starchy,
F o e d s such as:
Bread
Dltsnsr re), hagsl
-Cassai
,

Rtes, nootte, pasta

i ens. s t e
t »g.
1 cup csr 1
ssati
package
t f t sip e«*ed

1 or 3e$g
servings per day
or
Never sat

£ servings
P«?F day

3 savings
per (jay

4 or more
servings per day

2-S servings
per day

4-S sarvfngg
pes' day

S <J? trtera
servings per <dsy

3-4 servings
per day

1-g sen/fogs
per day

Less Hsao 1
serving per rfsy
or
Never use

•' " x < S f

Y^S

Fruits m4 ¥egetat*t#8 such as:
Fa*; lre*rr ar

ftraeft

CSJIISSW

ft*

• i svg pises
«/8 cup

.

. (J s*»
serving) •
OA)d fruis
2 Tfcbfespoafis • t or iess
orEwg.'
servings per day
pieces •
or
VegMstite: fresh, fsaerj,
1£ eup (1 scg. Never sat
, or
fiwtwd
. ssjvisg)
'
Lewies salad
» cup' f l sresS.
jjcwi)
Potato (tested, ftaahsd, i small or iffl
or o&sr}
; cup
• Juice: fttiii or vsgstaWa
1/2 l i p (1
.sms* glass). .
A l c o h b J sucfi a s ;
Bear, ragote er
fight
Liqusr
Wins

,

FOIt OFFICE 4ISE O ^ L V

I

•

5 tart
t oocMsii or
1 jissef
1 smaii $em

5 or mom
servings psr day

#•1

Z-4

J Check here if you usually add salt at the table.
Check here if you eat more than 5 meals per week in restaurants or fast-food chains,

it you arefollowinga speciai diet or a vegetarian diet, enter name or type of diet here:

•Please dieck thatyou have circled 23 answers and that you havefilledin your name and trie date,
THANK YOIJ
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EPAT SCORING INSTRUCTIONS
NOTE: Secfjans-l and II are scored differentJy,.
P l e a s e carefully read and follow the instructions below.

SECTION 1: Higher-Fat Foods
Section I contains foods thai are higher in fat Fat in your diet can lead to increased risk tor heat disease;. Trie
Section I scora is an estimate of the amount of fat in your diet For your health, the lower the score, the
better. (The highest Scora you can get is 48. The lowest is 12.)
To get your Section I score. Seek at the "Par Office Use Only" strip at the end of SecSon U For every box you
crcied in column W (felt column) of Section I. give ycureeif 4 points. For every box circled in column X, 3 points.
Column Y. 2 points. Column 2 . 1 point Add up your points, andwrite the total hi the white box in the grid at the
beginning of Section i.
Remember, Column
Column
Column
Column

W=
X =
Y =
Z a

4
3
2
1

points
points
points
point

For example: After filBng outEPAT.Mary went down column Wand fcundthat she had circled 3 boxes. That
gives her 12 points for column W (3 boxes X 4 points =» 12 paints}. She counted 5 drcfed boxes in column X, so
trial is 15 points (S X 3 »IS). Fcrr column Y, she counted 3 circles for S points (3X 2 *8). And for column Z. Mary
had circled 1 box fori point (1 X 1 -.1). By adding her column scores. Maty got her Section t score: 34 points
(12 + 15 + 6 + 1 - 3 4 ) .

SECTION II: A-OK. Foods
Section II contains foods that are lower in fat These foods are gcod siiestilutBs for the hlgner-fat foods in SecSon
!. The Section H score is an estimate of the quantity of health-promoting low-fat foods in your diet For your
health, the higher the s c o r e , the better. nTjeJ^hestscorejOTcsm^&tfej**. Thetowest_tell.)
To get your Section U score, leck at th» "For Office Use Only" strip at the and of Section H. For every box you
circled in column W (left column) of Section It, give yourself 1 point For every box circled In column X, 2 points.
Column Y. 3 points. Column Z. 4 points. Add up your points, and writs the total in the white box in trie grid at the
beginning of Section It
Remember, Column
Column
Column
Column

W=
X =
Y s
Z =

cj9B7^1i»u<*imi(|!<>eMinnMo<»

1
2
3
4

point
points
points
points

(Nottca that the columns; get different
points than in Section I.) ^^

| For Use With EPAT Version 3 Only _ | '
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APPENDIX E - VAP-II RESULT SAMPLE SHEET
* r

"ft-YSID£N

8cb Smith

Dt

John

mix coo?aRj
4/29/2006

sjdirs

OFFICE LG£A713fc

I

G2/19/S5
0574S62

JM

PhOGIU ^ /

WTE^fflMC-

7l7

5/01/2006
5/04/2006

AtX£SS*3NfK>

DAIS K-PORIfO-

^t}"«•rof•ec^

025496

Cere

1

V

J

Directly treasured l a u d "Pastel
T o t a l M5L-Choiesterol - Direct104 i s ^ / d i
( D e s i r a b l e r a n g e <100 agr/dl. f o r CHD, D i a b e t e s , o r i t s e q u i v a l e n t )

<130 pig/cil

Q

~. T o t a l ; HW*<5holes j;ero|iS;;|3i*ct;- ; ; : E
T o t a l ; VXipL-chGleste^cl; -

triglycerides -

Direct

Direct

68 sig/dl.

<30 mg/effi

440 mf/dL

<15-0 iag/dS

.120 mg/sft

< J 0 3 mgftO,;

24 msjMV

30

•6a mg/<tt

«eieo i«r/<a

T o t a l 'fca^HlS. O i t j J ^ s t i i ^ • (lttj,U* ::<rt.BL)
I ' o t a l apoBjoa: i c a l c )
For Clmical Judgement in Setting LDt-C Sua
•^jj(a)

Cholesterol

R e a l U2fc C h o l e s t e r o l

mg/dL
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Q

^;iffi&^«fl> ; B S sdgii S p ^ 3 : £ j :
s e a l 19L-C s i s e p a t t e r n

:i ...)...,

:R^Mt::i;ia,fi^oMii)s^:tSftS*jfflitif:

ft

*

>• ) • > » > •

JRIBS/O*;1:

<3jQ-:^ftS|M

>

•CGnstsllatio&.,©£ . i i p i d . - r i ^ J c f a c t o r s
.Small denqfi I>3L# . E l e v a t e d Si3> LOW K:DX.

HQJX2 (l,£x-ge, Buoya R t ; most
HD1--3 {Small,

Dense.; l&ast

VLDt-3 {Small

Remnant!

protective)

S «j/dL

>10 Big/dL

fej

IKIAH,

>3<3 mg/dL

59 ing/dL

-'10 Big/dl,

n
KI

34

protective)

SVsr Lab Vfene Only; S u b s p e c i e s Real 1UX. (Gioles-fcenol coticKntr&fciQna i n sag/dl.)
£*t>I,j}
h&h%
UH,*
X-BL^
24. S
20.7
a.6
12.0
*~~ Pattern B
*
'
PattwwA
*
3<T1 Lo(«tpn »e*wav
BffSHWaWmi, A3. 3b3H

A Better Cholesterol Test

V

r««; A<SS 3iw*«3
tsftDueeiw; Kris Kstfcarro
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www.thevaptest.com
^>20C4 Afteroiech

The next deadline for submitting project proposals to the Provost's Office for full review
is N/A. You may submit a project proposal for expedited review at any time.

Dr. Thomas R. Herrinton
Administrator, Institutional Review Board
University of San Diego
herrinton@sandiego.edu
5998 Alcala Park
San Diego, California 92110-2492
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